·
We are pleased to announce that Allegrow Biotech has secured investment from HKUST E-Fund, our alma mater's deep-tech investment vehicle that backs promising spinouts from HKUST research. This funding will accelerate development of our AimGel platform and expand our product lineup, empowering researchers working on immune cell therapies with better tools for T cell and NK cell activation and expansion. Our technology originated from research at HKUST's biomaterials laboratory, and this investment provides the resources to bring these innovations from the lab bench to research teams worldwide. We're grateful for HKUST's continued support as we scale our capabilities to serve the cell therapy research community.
